ClinicalTrials.gg
CompletedNCT00817635Updated Jun 2, 2021Results posted

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

A Phase 2 interventional study of LCI699 and Eplerenone in Hypertension, sponsored by Novartis. Completed at 38 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-02.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 227 studies in Hypertension by Novartis — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · Novartis.

Enrollment
140th of 222
155 · median 309
Started
2008
with 24 others
Phase 2
29 of 227
2 open now
Registered
155th of 227
by date

Among the 227 studies in Hypertension by Novartis, this one is the 140th largest by enrollment of the 222 interventional ones that give a count, is one of 25 that started in 2008, is one of 29 in phase 2, and was the 155th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

4 of the 227 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies in Hypertension by Novartis, or all of them as a file.
02

Study summary

This study assessed the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in participants with resistant hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Blood Pressure
  • Hypertension
  • Resistant Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of hypertension with mean sitting systolic blood pressure (MSSBP) ≥140 millimeters of mercury (mmHg) and \<180 mmHg
  • Stable on a three-drug regimen (including a diuretic) for at least 4 weeks for the treatment of resistant hypertension
  • Male and female participants 18 to 75 years of age

Exclusion criteria

Exclusion criteria:

  • Recent history of myocardial infarction (MI), heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or
  • electrocardiography () findings related to cardiac conduction defects
  • Type 1 diabetes or uncontrolled type 2 diabetes ( [HbA1c] >9%)
  • within the last 5 years (excluding basal cell skin cancer)

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    LCI699 0.25 mg BID

    Following a 2-week placebo run-in period, participants received LCI699 0.25 mg, capsules, orally, twice daily (BID), with or without food for up to 8 weeks.

    Drug: LCI699

  • Experimental
    LCI699 1 mg QD

    Following a 2-week placebo run-in period, participants received LCI699 1 mg, capsules, orally, once daily (QD), with or without food for up to 8 weeks.

    Drug: LCI699

  • Experimental
    LCI699 0.5 mg followed by LCI699 1 mg BID

    Following a 2-week placebo run-in period, participants received LCI699 0.5 mg, capsules, orally, BID, with or without food for up to 4 weeks, followed by LCI699 1 mg, capsules, orally, BID with or without food for up to 4 weeks.

    Drug: LCI699

  • Active comparator
    Eplerenone 50 mg BID

    Following a 2-week placebo run-in period, participants received eplerenone 50 mg, capsules, orally, BID, with or without food for up to 8 weeks.

    Drug: Eplerenone

  • Placebo comparator
    Placebo

    For a 2-week placebo run-in period, followed by 8 weeks of the treatment period, participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food.

    Drug: LCI699-matching Placebo · Drug: Eplerenone-matching Placebo

Interventions

  • DrugLCI699

    LCI699 oral capsules

  • Eplerenone oral capsules

  • DrugLCI699-matching Placebo

    LCI699-matching placebo oral capsules

  • DrugEplerenone-matching Placebo

    Eplerenone-matching placebo oral capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF)

    Arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSSBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and country as factors and Baseline MSSBP as a covariate.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Change From Baseline in MSDBP at Week 8 LOCF

    Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSDBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.

    Time frame: Baseline, Week 8

  2. Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8, as Measured by Office Blood Pressure (OBP)

    MSSBP response was defined as the percentage of participants with a MSSBP \<140 mmHg or a \>=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP \<140 mmHg for non-diabetic participants and \<130mHg for diabetic participants.

    Time frame: Week 8

  3. Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8, as Measured by OBP

    MSDBP response was defined as the percentage of participants with a MSDBP \<90 mmHg or a \>=10 mmHg reduction from baseline. MSDBP control was defined as the percentage of participants with a MSDBP \<90 mmHg for non-diabetic participants and \<80mHg for diabetic participants.

    Time frame: Week 8

  4. Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSSBP at Week 8

    Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSSBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSSBP as a covariate.

    Time frame: Baseline, Week 8

  5. Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSDBP at Week 8

    Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSDBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.

    Time frame: Baseline, Week 8

  6. Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP) at Week 8 LOCF, as Measured by Ambulatory Blood Pressure Measurement (ABPM)

    An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings, using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24-hour period. The change from Baseline in SBP was analyzed using ANCOVA with treatment and country as factors and Baseline MSSBP as a covariate.

    Time frame: Baseline, Week 8

  7. Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP) at Week 8 LOCF, as Measured by ABPM

    An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings, using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory diastolic blood pressure readings for the 24-hour period. The change from Baseline in DBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.

    Time frame: Baseline, Week 8

  8. Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime SBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM

    An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings using an automated validated monitoring device from Baseline to Week 4. The 24-hour SBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24-hour period. The change from Baseline in SBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.

    Time frame: Baseline, Week 4

  9. Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime DBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM

    An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings using an automated validated monitoring device from Baseline to Week 4. The 24-hour DBP was calculated by taking the mean of all ambulatory diastolic blood pressure readings for the 24-hour period. The change from Baseline in DBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.

    Time frame: Baseline, Week 4

  10. Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), Hyperkalemia, and Hyponatremia

    An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality. Hyperkalemia was defined as potassium level \>5.5 millimoles per liter (mmol/L). It is the medical term that describes a potassium level that's higher than normal. Hyponatremia was defined as sodium level \<135 mmol/L. It is the medical term that describes a sodium level that's lesser than normal.

    Time frame: AEs, Hyperkalemia, and Hyponatremia: From start of the study drug treatment up to 10 weeks; SAE: From signing of the informed consent up to 10 weeks

  11. Number of Participants With Cortisol Levels Below 500 Nmol/L at 1 Hour After Adrenocorticotropic Hormone (ACTH) Injection at Week 8

    Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was \<500 nanomoles per liter (nmol/L) at 1 hour after the injection.

    Time frame: 1-hour post-dose at Week 8

  12. Percent Change From Baseline in Renin-Angiotensin-Aldosterone-System (RAAS) Biomarker: Plasma Aldosterone (PA) in LCI699 Compared to Eplerenone 50 mg at Week 8 LOCF

    Percent change from Baseline was analyzed by ANCOVA model using PA values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.

    Time frame: Baseline, Week 8

  13. Percent Change From Baseline in RAAS Biomarker: Plasma Renin Activity (PRA) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

    Percent change from Baseline was analyzed by ANCOVA model using plasma renin values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.

    Time frame: Baseline, Week 8

  14. Percent Change From Baseline in RAAS Biomarker: Active Renin (ARC) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

    Percent change from Baseline was analyzed by ANCOVA model using active renin values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.

    Time frame: Baseline, Week 8

  15. Percent Change From Baseline in RAAS Biomarker: Ratio of PA to PRA in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

    Percent change from Baseline was analyzed by ANCOVA model using percent ratio of PA to PRA values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.

    Time frame: Baseline, Week 8

07

Results

Posted Jun 2, 2021

Participant flow

Participants took part in this study at 35 investigative sites in the United States and in Iceland from 22 December 2008 to 13 October 2009.

Participant flow — Overall Study
MilestoneLCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlacebo
Started3226313333
Completed2322282825
Not completed94358
Withdrew: Adverse event10011
Withdrew: Abnormal laboratory value(s)11001
Withdrew: Withdrawal by subject21012
Withdrew: Lost to follow-up01010
Withdrew: Administrative problems00001
Withdrew: Protocol violation51323

Outcome measures

PrimaryChange From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF)

Arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSSBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and country as factors and Baseline MSSBP as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Mean · mmHg
Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF)
mmHgLCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlacebo
Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF)-11.4 ± 2.96-13.1 ± 3.24-12.5 ± 2.96-18.7 ± 2.92-8.8 ± 2.87
SecondaryChange From Baseline in MSDBP at Week 8 LOCF

Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSDBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Mean · mmHg
Change From Baseline in MSDBP at Week 8 LOCF
mmHgLCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlacebo
Change From Baseline in MSDBP at Week 8 LOCF-4.5 ± 1.72-6.0 ± 1.88-6.1 ± 1.72-7.7 ± 1.69-4.8 ± 1.66
SecondaryPercentage of Participants With a MSSBP Response and MSSBP Control at Week 8, as Measured by Office Blood Pressure (OBP)

MSSBP response was defined as the percentage of participants with a MSSBP \<140 mmHg or a \>=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP \<140 mmHg for non-diabetic participants and \<130mHg for diabetic participants.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8, as Measured by Office Blood Pressure (OBP)
percentage of participantsLCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlacebo
MSSBP Response54.857.741.965.642.4
MSSBP Control51.650.032.353.136.4
SecondaryPercentage of Participants With a MSDBP Response and MSDBP Control at Week 8, as Measured by OBP

MSDBP response was defined as the percentage of participants with a MSDBP \<90 mmHg or a \>=10 mmHg reduction from baseline. MSDBP control was defined as the percentage of participants with a MSDBP \<90 mmHg for non-diabetic participants and \<80mHg for diabetic participants.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8, as Measured by OBP
percentage of participantsLCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlacebo
MSDBP Response67.773.171.071.957.6
MSDBP Control54.865.458.156.354.5
SecondaryDose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSSBP at Week 8

Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSSBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSSBP as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Mean · mmHg
Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSSBP at Week 8
mmHgLCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BID
Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSSBP at Week 8-11.4 ± 2.96-13.1 ± 3.24-12.5 ± 2.96
SecondaryDose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSDBP at Week 8

Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSDBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Mean · mmHg
Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSDBP at Week 8
mmHgLCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BID
Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSDBP at Week 8-4.5 ± 1.72-6.0 ± 1.88-6.1 ± 1.72
SecondaryChange From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP) at Week 8 LOCF, as Measured by Ambulatory Blood Pressure Measurement (ABPM)

An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings, using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24-hour period. The change from Baseline in SBP was analyzed using ANCOVA with treatment and country as factors and Baseline MSSBP as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Mean · mmHg
Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP) at Week 8 LOCF, as Measured by Ambulatory Blood Pressure Measurement (ABPM)
mmHgLCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlacebo
24-hour Mean SBP-4.4 ± 3.22-5.7 ± 2.87-6.3 ± 2.47-15.7 ± 2.59-1.0 ± 2.59
Daytime Mean SBP-4.9 ± 3.29-6.0 ± 2.92-6.3 ± 2.52-15.7 ± 2.65-1.6 ± 2.65
Nighttime Mean SBP-3.2 ± 3.49-4.8 ± 3.13-7.0 ± 2.67-15.4 ± 2.810.4 ± 2.81
SecondaryChange From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP) at Week 8 LOCF, as Measured by ABPM

An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings, using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory diastolic blood pressure readings for the 24-hour period. The change from Baseline in DBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Mean · mmHg
Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP) at Week 8 LOCF, as Measured by ABPM
mmHgLCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlacebo
24-hour Mean DBP1.0 ± 2.15-3.4 ± 1.94-3.7 ± 1.67-9.6 ± 1.74-0.2 ± 1.74
Daytime Mean DBP0.6 ± 2.31-3.6 ± 2.06-3.4 ± 1.78-9.5 ± 1.86-0.8 ± 1.87
Nighttime Mean DBP1.9 ± 2.17-2.5 ± 1.98-4.6 ± 1.69-9.6 ± 1.751.2 ± 1.76
SecondaryChange From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime SBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM

An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings using an automated validated monitoring device from Baseline to Week 4. The 24-hour SBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24-hour period. The change from Baseline in SBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.

Time frame:
Baseline, Week 4
Reported as:
Mean · mmHg
Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime SBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM
mmHgLCI699 1 mg QDLCI699 0.5 mg BID
24-hour Mean SBP-7.8 ± 2.72-4.7 ± 2.29
Daytime Mean SBP-8.1 ± 2.69-5.3 ± 2.27
Nighttime Mean SBP-6.8 ± 3.17-4.5 ± 2.70
SecondaryChange From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime DBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM

An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings using an automated validated monitoring device from Baseline to Week 4. The 24-hour DBP was calculated by taking the mean of all ambulatory diastolic blood pressure readings for the 24-hour period. The change from Baseline in DBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.

Time frame:
Baseline, Week 4
Reported as:
Mean · mmHg
Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime DBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM
mmHgLCI699 1 mg QDLCI699 0.5 mg BID
24-hour Mean DBP-4.3 ± 1.98-2.5 ± 1.67
Daytime Mean DBP-3.9 ± 2.04-2.6 ± 1.73
Nighttime Mean DBP-4.5 ± 2.21-2.8 ± 1.87
SecondaryNumber of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), Hyperkalemia, and Hyponatremia

An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality. Hyperkalemia was defined as potassium level \>5.5 millimoles per liter (mmol/L). It is the medical term that describes a potassium level that's higher than normal. Hyponatremia was defined as sodium level \<135 mmol/L. It is the medical term that describes a sodium level that's lesser than normal.

Time frame:
AEs, Hyperkalemia, and Hyponatremia: From start of the study drug treatment up to 10 weeks; SAE: From signing of the informed consent up to 10 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), Hyperkalemia, and Hyponatremia
ParticipantsLCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlacebo
AE(s)151581316
SAE(s)00010
Hyperkalemia [potassium level >5.5 mmol/L]20001
Hyperkalemia [potassium level ≥6.0 mmol/L]20000
Hyponatremia [sodium level <130 and ≥125 mmol/L]00010
Hyponatremia [sodium level <135 mmol/L and ≥130mmol/L]32732
SecondaryNumber of Participants With Cortisol Levels Below 500 Nmol/L at 1 Hour After Adrenocorticotropic Hormone (ACTH) Injection at Week 8

Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was \<500 nanomoles per liter (nmol/L) at 1 hour after the injection.

Time frame:
1-hour post-dose at Week 8
Reported as:
Count of participants · Participants
Number of Participants With Cortisol Levels Below 500 Nmol/L at 1 Hour After Adrenocorticotropic Hormone (ACTH) Injection at Week 8
ParticipantsLCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlacebo
Number of Participants With Cortisol Levels Below 500 Nmol/L at 1 Hour After Adrenocorticotropic Hormone (ACTH) Injection at Week 801400
SecondaryPercent Change From Baseline in Renin-Angiotensin-Aldosterone-System (RAAS) Biomarker: Plasma Aldosterone (PA) in LCI699 Compared to Eplerenone 50 mg at Week 8 LOCF

Percent change from Baseline was analyzed by ANCOVA model using PA values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.

Time frame:
Baseline, Week 8
Reported as:
Geometric least squares mean · percent change in aldosterone
Percent Change From Baseline in Renin-Angiotensin-Aldosterone-System (RAAS) Biomarker: Plasma Aldosterone (PA) in LCI699 Compared to Eplerenone 50 mg at Week 8 LOCF
percent change in aldosteroneLCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BID
Percent Change From Baseline in Renin-Angiotensin-Aldosterone-System (RAAS) Biomarker: Plasma Aldosterone (PA) in LCI699 Compared to Eplerenone 50 mg at Week 8 LOCF-22.3 ± 0.16-30.4 ± 0.17-53.1 ± 0.15115.0 ± 0.15
SecondaryPercent Change From Baseline in RAAS Biomarker: Plasma Renin Activity (PRA) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

Percent change from Baseline was analyzed by ANCOVA model using plasma renin values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.

Time frame:
Baseline, Week 8
Reported as:
Geometric least squares mean · percent change in PRA
Percent Change From Baseline in RAAS Biomarker: Plasma Renin Activity (PRA) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF
percent change in PRALCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BID
Percent Change From Baseline in RAAS Biomarker: Plasma Renin Activity (PRA) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF41.6 ± 0.2474.3 ± 0.28107.7 ± 0.24414.1 ± 0.22
SecondaryPercent Change From Baseline in RAAS Biomarker: Active Renin (ARC) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

Percent change from Baseline was analyzed by ANCOVA model using active renin values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.

Time frame:
Baseline, Week 8
Reported as:
Geometric least squares mean · percent change in ARC
Percent Change From Baseline in RAAS Biomarker: Active Renin (ARC) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF
percent change in ARCLCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BID
Percent Change From Baseline in RAAS Biomarker: Active Renin (ARC) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF73.1 ± 0.2472.8 ± 0.27156.4 ± 0.23430.6 ± 0.22
SecondaryPercent Change From Baseline in RAAS Biomarker: Ratio of PA to PRA in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

Percent change from Baseline was analyzed by ANCOVA model using percent ratio of PA to PRA values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.

Time frame:
Baseline, Week 8
Reported as:
Geometric least squares mean · percent change in ratio of PA to PRA
Percent Change From Baseline in RAAS Biomarker: Ratio of PA to PRA in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF
percent change in ratio of PA to PRALCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BID
Percent Change From Baseline in RAAS Biomarker: Ratio of PA to PRA in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF-46.7 ± 0.26-50.0 ± 0.29-78.3 ± 0.25-57.1 ± 0.23

Adverse events

Collected over AEs: From start of the study drug treatment up to 10 weeks; SAE: From signing of the informed consent up to 10 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LCI699 0.25 mg BID0/32 (0%)0/32 (0%)15/32 (46.9%)
LCI699 1.0 mg QD0/26 (0%)0/26 (0%)15/26 (57.7%)
LCI699 0.5 mg Followed by LCI699 1 mg BID0/31 (0%)0/31 (0%)8/31 (25.8%)
Eplerenone 50 mg BID0/33 (0%)1/33 (3%)13/33 (39.4%)
Placebo0/33 (0%)0/33 (0%)16/33 (48.5%)
Most frequent serious events
Most frequent serious events
EventLCI699 0.25 mg BIDLCI699 1.0 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlacebo
Cerebrovascular accidentNervous system disorders0/320/260/311/330/33
Most frequent other events
Showing 10 of 89
Most frequent other events
EventLCI699 0.25 mg BIDLCI699 1.0 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlacebo
Muscle spasmsMusculoskeletal and connective tissue disorders1/322/260/314/330/33
DizzinessNervous system disorders1/321/260/314/331/33
DiarrhoeaGastrointestinal disorders3/320/260/312/331/33
FatigueGeneral disorders0/321/261/313/332/33
HyponatraemiaMetabolism and nutrition disorders1/320/262/312/330/33
HyperhidrosisSkin and subcutaneous tissue disorders0/320/262/310/330/33
Blood cortisol decreasedInvestigations2/321/261/310/331/33
Blood creatinine increasedInvestigations2/320/260/310/330/33
Abdominal painGastrointestinal disorders0/320/260/311/332/33
HeadacheNervous system disorders0/321/261/310/332/33

Baseline characteristics

Full Analysis set (FAS) population included all participants who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)LCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlaceboTotal
Mean53.6 ± 10.3655.4 ± 9.5857.2 ± 10.7756.2 ± 7.7059.8 ± 9.3356.5 ± 9.69
Sex: Female, Male
Sex: Female, Male(Participants)LCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlaceboTotal
Female12813141158
Male201818192297
Baseline Mean Sitting Systolic Blood Pressure (MSSBP)
Baseline Mean Sitting Systolic Blood Pressure (MSSBP)(millimeters of mercury (mmHg))LCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlaceboTotal
Mean152.4 ± 11.21152.5 ± 9.79152.2 ± 7.58153.8 ± 8.92153.4 ± 9.61152.9 ± 9.39
Baseline Mean Sitting Diastolic Blood Pressure (MSDBP)
Baseline Mean Sitting Diastolic Blood Pressure (MSDBP)(mmHg)LCI699 0.25 mg BIDLCI699 1 mg QDLCI699 0.5 mg Followed by LCI699 1 mg BIDEplerenone 50 mg BIDPlaceboTotal
Mean91.8 ± 11.6889.2 ± 9.5688.9 ± 11.8989.1 ± 9.8490.1 ± 11.6589.8 ± 10.92
08

Study locations

38 sites
  • Horizon Research Group, Inc
    Mobile, Alabama 36608, United States
  • Cochise Clinical Research
    Sierra Vista, Arizona 85635, United States
  • Clinical Solutions Advantage
    Buena Park, California 90620, United States
  • Michael Waldman, MD
    Irvine, California 92618, United States
  • Long Beach Center for Clinical Research
    Long Beach, California 90806, United States
  • Clinical Trials Research
    Roseville, California 95661, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Metro Clinical Research
    Littleton, Colorado 80120, United States
  • Meridien Research
    Bradenton, Florida 34203, United States
  • Clinical Research of So. Florida
    Coral Gables, Florida 33134, United States
  • Jacksonville Heart Center
    Jacksonville Beach, Florida 32250, United States
  • FPA Clinical Research
    Kissimmee, Florida 34741, United States
  • Accelovance
    Melbourne, Florida 32935, United States
  • Cardio-Pulminary Associates
    Plantation, Florida 33317, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • Northwest Clinical Trials
    Boise, Idaho 83704, United States
  • Provident Clinical Research
    Addison, Illinois 60101, United States
  • Cedar-Crosse Research Centereet
    Chicago, Illinois 60607, United States
  • Provident Clinical Research
    Bloomington, Indiana 47403, United States
  • Accelovance
    South Bend, Indiana 46601, United States
  • Peter A. Holt
    Baltimore, Maryland 21239, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Chelsea Internal Medicine
    Chelsea, Michigan 48118, United States
  • New York Cardiovascular Associates
    New York, New York 10001, United States
  • Charlotte Clinical Research
    Charlotte, North Carolina 28211, United States
  • Northstate Clinical Research
    Lenoir, North Carolina 28645, United States
  • Community Research
    Cincinnati, Ohio 45245, United States
  • Tipton Medical & Diagnostic Center
    Tipton, Pennsylvania 16684, United States
  • Medical Research South
    Charleston, South Carolina 29407, United States
  • Mountain View Clinical Research Associates
    Greer, South Carolina 29651, United States
  • Clinical Research Associates, Inc
    Nashville, Tennessee 37203, United States
  • Punzi Medical Center
    Carrollton, Texas 75006, United States
  • KRK Medical Research
    Dallas, Texas 75230, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • Daniel Gottlieb, MD
    Burien, Washington 98166, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Gemini Scientific
    Madison, Wisconsin 83719, United States
  • Encode Clinic
    Reykjavik, SA, Iceland
09

References and documents

Publications

  • Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens. 2013 Oct;31(10):2085-93. doi: 10.1097/HJH.0b013e328363570c. PubMed 24107737 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2008 to primary completion in Oct 2009, 9 months.

Results were first posted in Jun 2021, 11 years 7 months after primary completion. A results delay was requested in Nov 2012.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 9 months is below that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2009
First posted
Jan 6, 2009
StartActual
Dec 22, 2008
Primary completionActual
Oct 13, 2009
CompletionActual
Oct 13, 2009
Results delay requested
Nov 30, 2012
Results first posted
Jun 2, 2021
Last update
Jun 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00817635
Lead sponsor
Novartis
Collaborators
Great Lakes Drug Development, Inc., Integrium
Responsible party
Sponsor
First posted
Jan 6, 2009
Start date
Dec 22, 2008
Primary completion
Oct 13, 2009
Completion
Oct 13, 2009
Results posted
Jun 2, 2021
Last update
Jun 2, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osilodrostat

Start the discussion